Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support…
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared…